generic times product news

Published Online: Monday, January 1, 2007

Bethanechol Chloride Tablets, USP

Marketed by: IMPAX Laboratories Inc (Hayward, Calif)

Compared to: Urecholine Tablets (Odyssey Pharmaceuticals Inc)

Indication: November 3, 2006—IMPAX Laboratories announced that it received FDA approval for its bethanechol chloride tablets, USP, 5, 10, 25, and 50 mg. These tablets are indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.

Dosage Form: Tablets: 5, 10, 25, and 50 mg

For More Information: www.impaxlabs.com

Doxycycline Tablets

Marketed by: Mylan Pharmaceuticals Inc (Pittsburgh, Pa), a subsidiary of Mylan Laboratories Inc

Compared to: Adoxa Tablets (Par Pharmaceuticals)

Indication: November 8, 2006—Mylan Laboratories Inc announced that it received FDA approval for its abbreviated new drug application for doxycycline tablets, 50, 75, and 100 mg. These tablets have been approved for the treatment of a wide range of infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Dosage Form: Tablets: 50, 75, and 100 mg

For More Information: www.mylan.com

Moexipril HCl Tablets

Marketed by: Paddock Laboratories Inc (Minneapolis, Minn)

Compared to: Univasc (Warner Lambert Co LLC)

Indication: November 30, 2006—Paddock Laboratories announced the availability of Moexipril HCl tablets. These tablets, which are AB-rated, are indicated for treatment of patients with hypertension. They may be used alone or in combination with thiazide diuretics.

Dosage Form: Tablets: 7.5 and 15 mg

For More Information: www.paddocklabs.com

Oxybutynin Chloride Extended-release Tablets

Marketed by: Teva Pharmaceuticals (North Wales, Pa)

Compared to: Ditropan XL (Alza Corp)

Indication: November 10, 2006—Teva Pharmaceuticals announced the introduction of Oxybutynin Chloride Extended-release Tablets. Oxybutynin chloride, which is AB-rated, is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Dosage Form: Tablets: 15 mg

For More Information: www.tevausa.com 888-TEVA USA (888-838-2872)

Pravastatin Tablets 10, 20, and 40 mg

Marketed by: Barr Pharmaceuticals Inc and its subsidiary, Pliva d.d. (Woodcliff Lake, NJ)

Compared to: Pravachol (Bristol-Myers Squibb)

Indication: November 28, 2006—Pliva, a subsidiary of Barr Pharmaceuticals Inc, received FDA approval for its abbreviated new drug application to manufacture and market Pravastatin tablets, 10, 20, and 40 mg. Pravastatin is indicated for the primary prevention of coronary events in hypercholesterolemic patients without clinically evident coronary heart disease, and secondary prevention of cardiovascular events in patients with clinically evident coronary heart disease.

Dosage Form: Tablets: 10, 20, and 40 mg

For More Information: www.barrlabs.com




Related Articles
No Result Found
Latest Issues
$auto_registration$